Experienced in Attention Deficit Hyperactivity Disorder (ADHD)

Dr. Susan L. Mcelroy

Psychiatry
Lindner Center Of Hope Professional Associates
4075 Old Western Row Rd, 
Mason, OH 
Accepting New Patients
Experienced in Attention Deficit Hyperactivity Disorder (ADHD)
Lindner Center Of Hope Professional Associates
4075 Old Western Row Rd, 
Mason, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susan Mcelroy is a Psychiatrist in Mason, Ohio. Dr. Mcelroy is rated as an Experienced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Her top areas of expertise are Bipolar Disorder (BPD), Bulimia, Anorexia, and Major Depression. Dr. Mcelroy is currently accepting new patients.

Her clinical research consists of co-authoring 298 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Attention Deficit Hyperactivity Disorder (ADHD).

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

LINDNER CENTER OF HOPE PROFESSIONAL ASSOCIATES
4075 Old Western Row Rd, Mason, OH 45040

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression
An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression
Enrollment Status: Completed
Publish Date: August 12, 2025
Intervention Type: Drug
Study Drug: MYDAYIS
Study Phase: Phase 2
A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder
A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder
Enrollment Status: Completed
Publish Date: March 12, 2025
Intervention Type: Drug, Other
Study Drug: Liraglutide
Study Phase: Phase 2
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Enrollment Status: Completed
Publish Date: July 16, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder
A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Binge Eating Disorder
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder
A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 3
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode
Enrollment Status: Completed
Publish Date: May 14, 2020
Intervention Type: Other
View 6 Less Clinical Trials

298 Total Publications

Sodium-Glucose Cotransporter 2 Inhibitors for Lithium-Associated Kidney Dysfunction in Mood Disorders: A Real-World Historical Cohort Study.
Sodium-Glucose Cotransporter 2 Inhibitors for Lithium-Associated Kidney Dysfunction in Mood Disorders: A Real-World Historical Cohort Study.
Journal: medRxiv : the preprint server for health sciences
Published: September 15, 2025
Similar Doctors
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Vivekananda R. Rachamallu
Psychiatry
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Vivekananda R. Rachamallu
Psychiatry

Lindner Center Of Hope Professional Associates

4075 Old Western Row Rd, 
Mason, OH 
 (0.1 miles away)
513-536-4673
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vivekananda Rachamallu is a Psychiatrist in Mason, Ohio. Dr. Rachamallu is rated as an Advanced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). His top areas of expertise are Oppositional Defiant Disorder (ODD), Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), and Attention Deficit Hyperactivity Disorder (ADHD). Dr. Rachamallu is currently accepting new patients.

Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Mark C. Johnson
Child and Adolescent Psychiatry | Psychiatry
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Mark C. Johnson
Child and Adolescent Psychiatry | Psychiatry

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (17.5 miles away)
513-636-4200
Languages Spoken:
English, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Johnson is a Child and Adolescent Psychiatrist and a Psychiatrist in Cincinnati, Ohio. Dr. Johnson is rated as an Advanced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). His top areas of expertise are Asperger's Syndrome, Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive-Compulsive Disorder (OCD). Dr. Johnson is currently accepting new patients.

Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Tasha M. Wadley
Pediatrics | Psychiatry
Advanced in Attention Deficit Hyperactivity Disorder (ADHD)
Dr. Tasha M. Wadley
Pediatrics | Psychiatry
3333 Burnet Ave, Ml 5026, 
Cincinnati, OH 
 (17.5 miles away)
513-636-7722
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tasha Wadley is a Pediatrics specialist and a Psychiatrist in Cincinnati, Ohio. Dr. Wadley is rated as an Advanced provider by MediFind in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Her top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD), Delayed Growth, Obesity in Children, and Opioid Use Disorder. Dr. Wadley is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcelroy's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile